AGENDA

THURSDAY, OCTOBER 20, 2005

5:00 pm – 8:00 pm
Registration

6:00 pm – 8:00 pm
Registration Welcome Reception

FRIDAY, OCTOBER 21, 2005

7:00 am – 8:00 am
Breakfast

8:00 am – 8:10 am
Introduction and Opening Remarks

Karel Pacak
President ISP2005

Owen Rennert
Scientific Director NICHD

8:10 am – 10:00 am

SESSION 1
Pheochromocytoma: A Kaleidoscope of Presentations and a Minefield for Differential Diagnosis
Chairs: William M. Manger and Pierre-Francois Plouin

8:10 am – 8:40 am
Diagnostic Challenges and Vagaries of Pheochromocytoma
William M. Manger

8:40 am – 9:00 am
Clinical Characteristics of Incidentally-Discovered Pheochromocytoma Based on Experience in 50 Proven Cases
Emmanuel L. Bravo

9:00 am – 9:15 am
Clinical Experience with 1080 Adrenal Incidentalomas Observed at a Single Endocrinological Center: A Place for Chromaffin Tumors
Anna Kasperlik-Zaluska

9:15 am – 9:30 am
Characteristics of pheochromocytoma in a 4-20 year old population
Marta Barontini


9:30 am – 9:45 am
Pheochromocytoma During Pregnancy: A Literature Survey
Henri Timmers

9:45 am – 10:00 am
Lack of Symptomatology in Patients with Histological Evidence of Pheochromocytoma: A Diagnostic Challenge
Debbie L. Cohen

10:00 am – 10:30 am
Coffee Break

10:30 am – 12:30 pm

SESSION 2
Genetics: Increasing Importance for Clinical Decision-Making
Chairs: Hartmut Neumann and Diana Benn

10:30 am – 10:50 am
Predictors and Prevalence of Paraganglioma Syndrome Associated with Mutations of the SDHC Gene
Hartmut Neumann

10:50 am – 11:10 am
Genetic Analysis of Pheochromocytoma: The Rotterdam Experience
Winand N.M. Dinjens

11:10 am – 11:30 am
Molecular Genetic Analysis of the NF1 Gene in Neurofibromatosis-Associated Pheochromocytoma
Birke Bausch


11:30 am – 11:45 am
Candidate Gene Mutation Analysis in Pediatric Pheochromocytomas
Ronald R. de Krijger

11:45 am – 12:00 pm
Familial Non-Syndromic Pheochromocytoma
Giuseppe Opocher

12:00 pm – 12:15 pm
Genetic Mutation Screening in an Italian Cohort of Non-Syndromic Pheochromocytoma/Paraganglioma Patients
Maurizio Castellano

12:15 pm – 12:30 pm
Importance of SDHB Mutation Testing in Patients with Malignant Pheochromocytoma
Frederieke Brouwers

12:30 pm – 1:30 pm
Lunch

1:30 pm – 3:30 pm

SESSION 3
Pheochromocytoma/Paraganglioma Syndromes
Chairs: Ronald de Krijger and Patricia Dahia

1:30 pm – 1:50 pm
Paragangliomas: Clinical Overview
William F. Young, Jr


1:50 pm – 2.10 pm
Genetics of Pheochromocytoma/Paraganglioma Syndromes
Anne-Paule Gimenez-Roqueplo

2:10 pm – 2.30 pm
SDHD, SDHB Mutations: Different Phenotype and Penetrance (International SDH Consortium)
Diana Benn


2:30 pm – 2:45 pm
Mutational Spectrum of Paragangliomas Obtained from Archival Paraffin Sections
Jeffrey Kant

2:45 pm – 3:00 pm
Sporadic SDHB Mutation in an Extra-Adrenal Pheochromocytoma
Francien H. Van Nederveen

3:00 pm – 3:15 pm
SDHD Founder Mutation in Italian Families with Head and Neck Paraganglioma
Francesca Schiavi

3:15 pm – 3:30 pm
Coffee Break


3:30 pm – 5:30 pm

SESSION 4
Tumor Biology, Molecular Pathways of and Genotype/Phenotype Relationships
Chairs: Len Neckers and Robert Gagel

3:30 pm – 3:50 pm
Role of Familial Pheochromocytoma Genes in Developmental Culling of Sympathetic Progenitors
William Kaelin

3:50 pm – 4:10 pm
RET Receptor Signalling: Dissecting Receptor Function and Dysfunction
Lois Mulligan

4:10 pm – 4:30 pm
Hereditary Paraganglioma: An Emerging Link Between Krebs Cycle and Hypoxic Signaling
Bora E. Baysal

4:30 pm – 4:45 pm
Linking Hypoxia and Redox Signals in Pheochromocytoma: Transcription Association of VHL and SDH Mutations
Patricia Dahia

4:45 pm – 5:00 pm
Expression of mRNAs for Succinate Dehydrogenase Subunits and Related Genes in Pheochromocytoma
Kazumasa Isobe


5:00 pm – 5:15 pm
Low SDHB Expression by Immunohistochemistry Discriminates Pheochromocytoma with SDHB, SDHD and VHL Mutations from Other Hereditary Forms
Sandro Santagata

5:15 pm – 5:30 pm
Mouse Pheochromocytoma Cell Lines Reveal Transcriptional Silencing of Adrenergic Phenotype by Neurotrophin and cAMP
Marian J. Evinger

5:30 pm — 9:30 pm
Poster Viewing and Tours (with refreshments and light food)
Chairs: Salvatore Benvenga and Harry Keiser

7:00 am – 8:00 am
Breakfast

7:00 am – 8:30 am
Patient Breakfast Breakout Session

8:30 am – 10:30 am

SESSION 5
Biochemical Diagnosis and Tumor Localization
Chairs: David Goldstein and James Sisson

8:30 am – 8:50 am
Plasma Free Metanephrines for Diagnosis of Pheochromocytoma: False Positives and Effects of Sampling Conditions
Jacques W.M. Lenders

8:50 am – 9:10 am
Advancements in Biochemical Diagnosis of Pheochromocytoma
Ravinder Singh

9:10 am – 9:25 am
Multicenter Study on the Diagnostic Value of a New RIA for the Detection of Free Plasma Metanephrines in the Work-Up for Pheochromocytoma
Tomas Lenz

9:25 am – 9:40 am
Diagnostic Value of Plasma and Urinary Metanephrines and Catecholamines for the Diagnosis of Pheochromocytoma in Patients with Adrenal mass
Stephan Petersenn

9:40 am – 10:00 am
Evolving Role of PET Imaging for Diagnostic Localization of Pheochromocytoma
Karel Pacak

10:00 am – 10:15 am
Elusive Pheochromocytomas: Detection with Functional Imaging Using MIBG and FDG PET
Barry L. Shulkin

10:15 am – 10:45 am
Coffee Break

10:45 am – 12:30 pm

SESSION 6
Management and Treatment of Pheochromocytoma
Chair: Emmanuel L. Bravo and Robert Udelsman

10:45 am – 11:05 am
Risk Oriented Surgical Approach to Hereditary Pheochromocytoma
Henning Dralle

11:05 am – 11:25 am
The Course of Urinary Metanephrine Excretion in Recurrent and Malignant Pheochromocytoma
Pierre-Francois Plouin

11:25 am – 11:45 am
Mortality Associated with Pheochromocytoma: Increased Risk of Additional Tumors
Amir Khorram-Manesh

11:45 am – 12:00 pm
Clinical Analysis and Management of Pheochromocytoma: Experience from 360 Cases in Peking Union Medical College Hospital (PUMCH), Beijing, China
Zheng-pei Zeng

12:00 pm – 12:15 pm
Magnesium Sulfate in the Perioperative Management of Pheochromocytoma
Michael F. James

12:15 pm – 12:30 pm
Treatment of Bilateral Pheochromocytoma and Adrenal Medullary Hyperplasia
Svante Jansson

12:30 pm – 1:30 pm
Lunch

1:30 pm– 3:30 pm

SESSION 7
Malignant Pheochromocytoma
Chairs: Jon P. Gockerman and Karel Pacak

1:30 pm – 1:50 pm
Phase II Study of High-Dose 131I-MIBG Therapy for Patients with Malignant Pheochromocytoma and Paraganglioma
Paul A. Fitzgerald

1:50 pm – 2:10 pm
131I-MIBG Radiotherapy: Long-term Experience with Treatment of Malignant Pheochromocytoma and Paraganglioma
Jon P. Gockerman

2:10 pm – 2:25 pm
AT2 Receptor Stimulation May Halt Progression of Pheochromocytoma
Morris J. Brown

2:25 pm – 2:40 pm
Can Quantification of VMAT and SSTR Expression be Helpful for Planning Radionuclide Therapy of Malignant Pheochromocytomas
Lars Kölby

2:40 pm – 2:55 pm
Development of Novel Tools for the Diagnosis and Prognosis of Pheochromocytomas Using Peptide Marker Immunoassay and Gene Expression Profiling Approaches
Youssef Anouar

2:55 pm – 3:15 pm
Gene Expression Profiling of Benign and Malignant Pheochromocytoma: New Markers for Prognosis and Targets for Treatments
Peter Munson & Graeme Eisenhofer

3:15 pm – 3:30 pm
Progress in Identifying New Markers of Malignancy and Therapeutic Targets for Treatment: Can This be Facilitated by Collaborative and Coordinated Approaches?
Discussion period

3:30 pm – 4:00 pm
Coffee Break

4:00 pm – 6:30 pm

BREAKOUT SESSIONS

For more information on the breakout sessions, please click here.

A: Genetics and Pheochromocytoma/Paraganglioma Syndromes
Discussion Leaders: Robert Dluhy and Stefan Bornstein

Speakers:
• Joyce Graff– Pheos as clues to syndromes
• Robert Gagel – Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?"
• Hartmut Neumann– Germ-line mutation testing in pheochromocytoma - Who benefits?

B: Biochemical Diagnosis and Localization: Can We Reach a Consensus?
Discussion Leaders: Ashley B. Grossman and Hendrik Lehnert

Speakers:
• Debra Harlander — Challenges of biochemical testing: A patient perspective
• Anna M. Sawka – Recent developments in biochemical testing for pheochromocytoma
• Graeme Eisenhofer – A practical approach to efficient and cost-effective biochemical diagnosis of pheochromocytoma: the NIH perspective
• Rodney Reznek – Cross-sectional imaging of pheochromocytomas and paragangliomas: what are we trying to achieve?
• James Sisson – Pheochromocytomas: When, where and why

C: Management and Treatment of Pheochromocytoma
Discussion Leaders: Håkan Ahlman and Massimo Mannelli

Speakers:
• Håkan Ahlman and Massimo Mannelli – Background and objectives of the breakout session
•Robert Karnell – Malignant pheochromocytoma: The patients’ perspective
• Eva Forssell-Aronsson – Radionuclide aspects in the treatment of malignant pheochromocytoma
• Tito Fojo – Present and future therapies for malignant pheochromocytoma

D: Pathology of Pheochromocytoma and Extra-adrenal Paraganglioma
Discussion Leaders: Arthur Tischler and Noriko Kimura

Speakers:
• Arthur Tischler– Background and objectives of the breakout session
• Maria Merino – Pheochromocytoma and paraganglioma at the NIH
•Anne McNicol – Pheochromocytoma and paraganglioma in the UK
•Noriko Kimura – Histological grading and prognosis of pheochromocytoma and paraganglioma in Japan

7:30 pm – 10:00 pm
Dinner Reception

SUNDAY, OCTOBER 23, 2005

7:00 am – 8:00 am
Breakfast


8:00 am – 9:30 am
General Discussion of Breakout Sessions (Genetics & Biochemical Diagnosis)

9:30 am – 10:00 am
Coffee break

10:00 am – 11:30 am
General Discussion of Breakout Sessions (Management and Pathology)

11:30 am – 12:30 pm
PRESSOR Business Meeting and Official Close of Meeting

BACK TO TOP